Harmony Biosciences Holdings, Inc. today announced strong preliminary, unaudited net product revenue for Q4 and full year ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...
Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...
Novo Nordisk first to market with Wegovy pill Analysts see potential but question if pills are a 'game changer' Advantage for Novo could be short-lived, analysts say The approval of Novo's Wegovy pill ...
Novo Nordisk NOVO.B1.08%increase; green up pointing triangle filed for U.S. Food and Drug Administration approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...
Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, "Next-Generation ...
Dec 18 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, its once-weekly ...
Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.
These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback